A Review of the 2018 Asia-Pacific Working Group Consensus on Non-variceal Upper Gastrointestinal Bleeding.

Author: Joon Sung KIM ¹ ; Byung Wook KIM
Author Information

1. Division of Gastroenterology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. gastro@catholic.ac.kr
Publication Type:Brief Communication
Keywords: Non-variceal upper gastrointestinal bleeding; Guideline; Platelet aggregation inhibitors; Anticoagulants
MeSH: Anticoagulants; Consensus*; Hemorrhage*; Humans; Mortality; Platelet Aggregation Inhibitors
From:The Korean Journal of Gastroenterology 2019;73(1):16-18
CountryRepublic of Korea
Language:Korean
Abstract: Despite recent advances in endoscopic techniques and acid-suppressive therapies, non-variceal upper gastrointestinal bleeding (NVUGIB) is still associated with significant morbidity and mortality. The increased use of dual antiplatelet agents and oral anticoagulants has complicated the management of NVUGIB. Physicians often have to decide on when to discontinue and resume these medications in patients with NVUGIB. However, clinical data regarding the resumption of antiplatelets and anticoagulants are still minimal. Here, we report and summarize the key recommendations made in the recent Asia-Pacific guidelines regarding management of antithrombotics in patients with NVUGIB.